KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Sales: 2009-2025

Historic Return on Sales for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -0.16%.

  • Neogenomics' Return on Sales fell 4.00% to -0.16% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.16%, marking a year-over-year decrease of 4.00%. This contributed to the annual value of -0.12% for FY2024, which is 3.00% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Return on Sales is -0.16%, which was down 5.99% from -0.15% recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Return on Sales registered a high of 0.15% during Q2 2021, and its lowest value of -0.33% during Q3 2022.
  • Its 3-year average for Return on Sales is -0.15%, with a median of -0.15% in 2023.
  • Its Return on Sales has fluctuated over the past 5 years, first increased by 16bps in 2021, then tumbled by 45bps in 2022.
  • Neogenomics' Return on Sales (Quarterly) stood at -0.02% in 2021, then declined by 27bps to -0.28% in 2022, then climbed by 13bps to -0.15% in 2023, then grew by 3bps to -0.12% in 2024, then decreased by 4bps to -0.16% in 2025.
  • Its Return on Sales stands at -0.16% for Q3 2025, versus -0.15% for Q2 2025 and -0.12% for Q1 2025.